 | Related Articles |
Immunotherapy Toxicity.
Hematol Oncol Clin North Am. 2019 Apr;33(2):275-290
Authors: Mantia CM, Buchbinder EI
Abstract
The development of immunotherapy to target cancer has led to improved treatment of many types of malignancy. The immune checkpoint inhibitors are a class of medications that block cell signaling and allow the immune system to recognize and attack cancer cells. CTLA-4, PD-1, and PD-L1 inhibitors have been approved as treatment options in many different types of localized and advanced malignancies. Immune checkpoint inhibitors can be associated with unique side effects known as immune-related adverse events. Side effects most commonly occur in the skin, gastrointestinal tract, lung, and endocrine glands but can affect other organ systems as well.
PMID: 30833000 [PubMed - in process]